Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death From Any Cause

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
To examine, among once-daily LAMA using COPD patients, whether evening administration of LAMA is superior with respect to the incidence of hospitalization requiring AECOPD or death from all causes than the more conventional morning administration.
Epistemonikos ID: fd2391480073a632a6cc7050b07e96e84fe75203
First added on: May 13, 2024